Abstract | OBJECTIVE: PATIENTS AND METHODS: The study was a retrospective analysis of a consecutive cohort of adult patients diagnosed with T-PLL at Mayo Clinic Rochester from January 1, 1997, through September 30, 2014. RESULTS: A total of 41 patients were diagnosed with T-PLL per the World Health Organization 2008 classification. The median age was 66 years, and 23 (56%) were male. After a median follow-up of 18 months (range, 0.4-66.1 months), 32 patients (78%) had died, with a median overall survival of 16.9 months. Approximately half the cohort was treated with alemtuzumab, almost exclusively after 2004. Median survival for patients receiving intravenous alemtuzumab-based therapy was 40.5 versus 10.3 months for all other therapies (P = .0004). A significant survival difference between intravenous versus subcutaneous alemtuzumab administration of 40.5 versus 13.7 months was noted (P = .0014). Only 4 (14%) of 28 patients aged < 70 years underwent hematopoietic stem cell transplantation, with a median survival after transplantation of 4 months. CONCLUSION: In this large series of T-PLL patients treated at a single tertiary-care center, we confirmed the prior observation of the superiority of intravenous alemtuzumab over other therapies. Hematopoietic stem cell transplantation was feasible in a minority of potentially eligible patients. Early transplant referral should be considered for all eligible patients.
|
Authors | Moussab Damlaj, Nanna H Sulai, Jennifer L Oliveira, Rhett P Ketterling, Shahrukh Hashmi, Thomas Witzig, Grzegorz Nowakowski, Timothy G Call, Tait D Shanafelt, Wei Ding, William J Hogan, Mark R Litzow, Mrinal M Patnaik |
Journal | Clinical lymphoma, myeloma & leukemia
(Clin Lymphoma Myeloma Leuk)
Vol. 15
Issue 11
Pg. 699-704
(Nov 2015)
ISSN: 2152-2669 [Electronic] United States |
PMID | 26422251
(Publication Type: Journal Article)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Alemtuzumab
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Alemtuzumab
- Antibodies, Monoclonal, Humanized
(administration & dosage, therapeutic use)
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Chromosome Aberrations
- Drug Administration Routes
- Female
- Follow-Up Studies
- Hematopoietic Stem Cell Transplantation
- Humans
- Induction Chemotherapy
- Leukemia, Prolymphocytic, T-Cell
(diagnosis, drug therapy, mortality, therapy)
- Male
- Middle Aged
- Retrospective Studies
- Salvage Therapy
- Treatment Outcome
|